PDCD1 and glioblastoma: For example, in the CheckMate 143 randomised phase III clinical trial, 369 patients with first recurrence of glioblastoma after standard chemoradiotherapy were randomised to receive the PD1 inhibitor, nivolumab (n = 184) or the angiogenesis inhibitor, bevacizumab (n = 185).